Health Outlook Raises $4 Million

Howard Sams

New York-based Health Outlook, which has developed technology to improve healthcare via advanced study of proteins in the human body, has raised $4 million from four investors, according to an SEC filing. The company, whose early investors include New York-based Emerald Bioventures, has so far raised $9.6 million.

Tim Opler, Ph.D., and private investor John Rydzewski co-founded Health Outlook in 2021, with the aim of using proteomics — advanced analysis of proteins — to predict health events and to improve health outcomes.

Opler is the founding principal of Torreya Partners, a healthcare investment bank in New York. He has previously served at wealth management firm Stifel and Credit Suisse, besides teaching finance at Ohio State University. Like Opler, Rydzewski has extensive experience in healthcare investing. He has served as chairman of RAND Health’s board of advisors and a member of the University of Pennsylvania School of Nursing’s board of advisors.

Health Outlook says it combines proteomics with advanced statistical and artificial intelligence techniques to help real-world medical practice. Over a longer period, it expects to apply advanced algorithms to support measures that can shift the human life expectancy curve higher.

Howard Sams, a senior healthcare executive at Siemens Healthineers who went on to hold global roles at Siemens, Roche Diagnostics and Boston Scientific, serves as Health Outlook’s CEO. He has served as a partner at Emerald Bioventures, and currently sits on the board of data analytics firm Glassbeam.